ALT1 Stock Chart & Stats
$50.94
$0.00(0.00%)
At close: 4:00 PM EDT
$50.94
$0.00(0.00%)
Day’s Range― - ―
52-Week Range$1.00 - $111.00
Previous CloseN/A
Volume0.00
Average Volume (3M)2.00
Market Cap
$11.25B
Enterprise Value$273.45
Total Cash (Recent Filing)$326.32M
Total Debt (Recent Filing)$35.75M
Price to Earnings (P/E)―
Beta-0.18
Next Earnings
Nov 10, 2026EPS Estimate
-2.29Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.78
Shares Outstanding194,517,700
10 Day Avg. Volume6
30 Day Avg. Volume2
Financial Highlights & Ratios
PEG Ratio0.14
Price to Book (P/B)1.41
Price to Sales (P/S)7757.46
P/FCF Ratio-4.71
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$331.03Price Target Upside549.84% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
EPS Forecast (FY)-9.92
Revenue Forecast (FY)$31.75K
Bulls Say, Bears Say
Bulls Say
Clinical Pipeline AdvancementStarting a global Phase III trial materially advances pemvidutide toward potential commercialization in MASH. The broad site network and defined enrollment plan demonstrate clinical execution, expand the company’s development opportunity, and create a durable catalyst beyond early-stage research.
Strong Liquidity And Low LeverageA well-capitalized, low-leverage balance sheet gives Altimmune flexibility to fund major clinical programs without immediate dependence on debt markets. Management says current cash supports PERFORMA through its 52-week readout, strengthening continuity of development and reducing near-term solvency pressure.
Promising AUD Efficacy And Market PotentialPositive Phase II AUD results across drinking behavior, abstinence, and objective biomarkers support pemvidutide’s potential differentiation in a market with few effective therapies. The breadth of observed benefits may strengthen regulatory discussions and expand the candidate’s long-term commercial opportunity.
Bears Say
Persistent Losses And Cash BurnAltimmune remains entirely dependent on advancing clinical assets rather than recurring product revenue, while research and operating expenses generate substantial cash outflows. Persistent losses and negative cash flow consume shareholder capital and increase the funding required before any commercial revenue can emerge.
Funding Gap For Potential AUD Phase IIIA future AUD Phase III would require additional capital beyond the currently funded MASH plan. Management prefers royalties, debt, or partnerships, but those sources are not assured; securing them could affect trial timing, economics, strategic flexibility, or shareholder dilution.
Competitive And Tolerability Execution RiskMultiple competing Phase III programs could slow enrollment or raise trial costs, while gastrointestinal discontinuations may constrain dosing or treatment persistence. These issues could reduce development efficiency and complicate the evidence needed to support regulatory approval and eventual adoption.
Altimmune News
ALT1 FAQ
What was Altimmune Inc’s price range in the past 12 months?
Altimmune Inc lowest stock price was $1.00 and its highest was $111.00 in the past 12 months.
What is Altimmune Inc’s market cap?
Altimmune Inc’s market cap is $11.25B.
When is Altimmune Inc’s upcoming earnings report date?
Altimmune Inc’s upcoming earnings report date is Nov 10, 2026 which is in 61 days.
How were Altimmune Inc’s earnings last quarter?
Altimmune Inc released its earnings results on Aug 12, 2026. The company reported -$2.032 earnings per share for the quarter, beating the consensus estimate of -$2.303 by $0.271.
Is Altimmune Inc overvalued?
According to Wall Street analysts Altimmune Inc’s price is currently Undervalued.
Does Altimmune Inc pay dividends?
Altimmune Inc does not currently pay dividends.
What is Altimmune Inc’s EPS estimate?
Altimmune Inc’s EPS estimate is -2.29.
How many shares outstanding does Altimmune Inc have?
Altimmune Inc has 194,517,700 shares outstanding.
What happened to Altimmune Inc’s price movement after its last earnings report?
Altimmune Inc reported an EPS of -$2.032 in its last earnings report, beating expectations of -$2.303. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Altimmune Inc?
Currently, no hedge funds are holding shares in MX:ALT1
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Altimmune Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$331.03 (549.84% Upside)
$331.03 (549.84% Upside)
Blogger Sentiment
Bullish
MX:ALT1 Sentiment 89%
Sector Average 60%
Sector Average 60%
Insider Transactions
Bought Shares
Worth $747.8K over
the Last 3 Months
the Last 3 Months
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-9.43%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
176.97%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Altimmune Inc
Altimmune, Inc. is a clinical-stage biopharmaceutical company focused on pioneering treatments for obesity and various liver diseases. Its primary investigational drug, pemvidutide (proposed INN, previously known as ALT-801), operates as a GLP-1/glucagon dual receptor agonist. This compound is currently undergoing Phase 1b clinical trials, exploring its efficacy in treating both obesity and non-alcoholic steatohepatitis (NASH). Additionally, Altimmune is advancing HepTcell, an immunotherapeutic candidate, through Phase 2 clinical trials. This therapy is designed for individuals suffering from chronic hepatitis B virus infection. The enterprise, initially named Vaxin Inc., officially adopted the Altimmune, Inc. moniker in September 2015. Established in 1997, the company maintains its corporate headquarters in Gaithersburg, Maryland.
ALT1 Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed substantial clinical and operational momentum: initiation of a global Phase III in MASH, robust positive Phase II AUD data that met multiple registrational endpoints (including objective biomarker improvements and 9.1% weight loss), completed enrollment in ALD, and a strengthened balance sheet ($519M cash). Key positives notably outweigh near‑term risks, though important caveats remain — including higher operating expenses, GI-related tolerability signals under further review, a competitive MASH enrollment landscape, and the need to secure non-dilutive funding for a potential AUD Phase III (not covered by the current runway). Several pivotal readouts (RESTORE H2 2027, PERFORMA 52‑week in 2029) and regulatory engagements are upcoming and will be determinative for long-term value.View all MX:ALT1 earnings summariesALT1 Stock 12 Month Forecast
Average Price Target
$331.03
▲(549.84% Upside)